首页> 外文期刊>International Journal of Medical Sciences >Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer
【24h】

Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer

机译:过氧化物组织增殖物激活受体-α的上调和脂质代谢途径促进癌症癌的致癌物

获取原文
       

摘要

Ampullary cancer is a rare periampullary cancer currently with no targeted therapeutic agent. It is important to develop a deeper understanding of the carcinogenesis of ampullary cancer. We attempted to explore the characteristics of ampullary cancer in our dataset and a public database, followed by a search for potential drugs. We used a bioinformatics pipeline to analyze complementary (c)DNA microarray data of ampullary cancer and surrounding normal duodenal tissues from five patients. A public database from the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) was applied for external validation. Bioinformatics tools used included the Gene Set Enrichment Analysis (GSEA), Database for Annotation, Visualization and Integrated Discovery (DAVID), MetaCore, Kyoto Encyclopedia of Genes and Genomes (KEGG), Hallmark, BioCarta, Reactome, and Connectivity Map (CMap). In total, 9097 genes were upregulated in the five ampullary cancer samples compared to normal duodenal tissues. From the MetaCore analysis, genes of peroxisome proliferator-activated receptor alpha (PPARA) and retinoid X receptor (RXR)-regulated lipid metabolism were overexpressed in ampullary cancer tissues. Further a GSEA of the KEGG, Hallmark, Reactome, and Gene Ontology databases revealed that PPARA and lipid metabolism-related genes were enriched in our specimens of ampullary cancer and in the NCBI GSE39409 database. Expressions of PPARA messenger (m)RNA and the PPAR-α protein were higher in clinical samples and cell lines of ampullary cancer. US Food and Drug Administration (FDA)-approved drugs, including alvespimycin, trichostatin A (a histone deacetylase inhibitor), and cytochalasin B, may have novel therapeutic effects in ampullary cancer patients as predicted by the CMap analysis. Trichostatin A was the most potent agent for ampullary cancer with a half maximal inhibitory concentration of 0.3 μM. According to our results, upregulation of PPARA and lipid metabolism-related genes are potential pathways in the carcinogenesis and development of ampullary cancer. Results from the CMap analysis suggested potential drugs for patients with ampullary cancer.? The author(s).
机译:随机癌是目前没有靶向治疗剂的罕见血浆癌。重要的是要更深入地了解患有安瓿癌的致癌物。我们试图探讨我们数据集和公共数据库中Ampullary癌症的特征,然后进行潜在的药物。我们使用生物信息化管道来分析互补(C)DNA微阵列数据的综合癌症,并从五名患者周围围绕正常十二指肠组织。来自国家生物技术信息基因表达式综合症(NCBI Geo)的公共数据库用于外部验证。使用的生物信息学工具包括基因集浓缩分析(GSEA),用于注释,可视化和集成发现(David),Metacore,Kyoto Encyclopia的基因和基因组(Kegg),标志,生物公园,反应和连接地图(CMAP)数据库。与正常的十二指肠组织相比,总共有9097个基因在五个大癌癌样品中上调。从Metacore分析中,过氧化物体增殖物激活的受体α(PPARA)和类视黄醇X受体(RXR)的基因在Ampullary癌组织中过表达。此外,GEGG,Hallmark,反应和基因本体数据库的GSEA表明,PPARA和脂质代谢相关基因在我们的Ampullary癌症和NCBI GSE39409数据库中富集。 PPARA信使(M)RNA的表达和PPAR-α蛋白在临床样本和疗法癌细胞中较高。美国食品和药物管理局(FDA) - 包括Alvespimycin,Trichostatin A(组蛋白脱乙酰酶抑制剂)和细胞蛋白B的批次药物可能在Ampullary癌症患者中具有新的治疗效果,如CMAP分析所预测的。 Trichostatin A是具有半最大抑制浓度的蜂鸣癌的最有效的药剂。 0.3μm。根据我们的结果,对pPARA和脂质代谢相关基因的上调是致癌和患有Ampullary癌症的潜在途径。 CMAP分析的结果表明患有安瓿癌患者的潜在药物。作者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号